18 February 2026 Edinburgh-based CRO Axol Bioscience, leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, announces that it has acquired the ophthalmology business of the Newcastle-based CRO Newcells Biotech. The acquisition of Newcells’ ophthalmology business includes its specialist team, facilities and intellectual property related to supply of proprietary iPSC-derived products and ophthalmology research services. Devel